Rush University Medical Center

Pathway to Cures Announces First Entrepreneur in Residence

Retrieved on: 
Monday, March 11, 2024
Other Philanthropy, Biotechnology, Pharmaceutical, Health, Philanthropy, Fund Raising, Foundation, Other Health, Disease, Coagulopathy, Sickle cell disease, Heredity, Spark Therapeutics, Rush University Medical Center, Entrepreneur in residence, Knowledge, Mortality, Baxalta, EIR, Doctor of Philosophy, MD, MBA, Therapy, Anemia, Blood

Pathway to Cures (P2C) announced today its first Entrepreneur in Residence (EIR), Leonard Valentino, M.D.

Key Points: 
  • Pathway to Cures (P2C) announced today its first Entrepreneur in Residence (EIR), Leonard Valentino, M.D.
  • Dr. Valentino most recently served as President and CEO of the National Bleeding Disorders Foundation (NBDF) and was instrumental in bringing Pathway to Cures into reality.
  • Pathway to Cures is the venture philanthropy fund of the NBDF focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community.
  • “My role as Entrepreneur in Residence for Pathway to Cures will be to provide guidance into the consideration and support of new opportunities for catalyzing transformative therapies and cures.

The Angelman Syndrome Foundation (ASF) and Cedars-Sinai Guerin Children's team up to launch new clinic for families living with Angelman syndrome

Retrieved on: 
Tuesday, February 20, 2024
Social work, Angelman syndrome, Diet, Physician, Rush University Medical Center, Prader–Willi syndrome, Hope, Common, Occupational therapy, Cedars-Sinai Medical Center, Genetics, DSM-IV codes, Walking, Patient, MPH, Speech, Spectrum, Cerebral palsy, UBE3A, Neurology, Gastroenterology, Seizure, Pharmaceutical industry

AURORA, Ill., Feb. 20, 2024 /PRNewswire-PRWeb/ -- The Angelman Syndrome Foundation is proud to announce a new collaboration with Cedars-Sinai Guerin Children's to launch a new clinic for patients with Angelman syndrome, a rare neuro-genetic disorder.

Key Points: 
  • The Angelman Syndrome Foundation is proud to announce a new collaboration with Cedars-Sinai Guerin Children's to launch a new clinic for patients with Angelman syndrome, a rare neuro-genetic disorder.
  • AURORA, Ill., Feb. 20, 2024 /PRNewswire-PRWeb/ -- The Angelman Syndrome Foundation is proud to announce a new collaboration with Cedars-Sinai Guerin Children's to launch a new clinic for patients with Angelman syndrome, a rare neuro-genetic disorder.
  • The clinic is led by Cesar Ochoa-Lubinoff, MD, MPH , director of Developmental-Behavioral Pediatrics at Cedars-Sinai Guerin Children's, who previously co-directed the Angelman syndrome clinic at Rush University Medical Center in Chicago.
  • "In my experience, families facing Angelman syndrome are resilient, but they need a supportive medical team in place," Ochoa-Lubinoff said.

OCCUPATIONAL HEALTH PHYSICIAN URGES CHICAGOANS TO WEAR MASKS/GET VACCINATED

Retrieved on: 
Friday, February 16, 2024
Hospital, N95, Workplace, Molina Healthcare, Medical director, SAP, Rush University Medical Center, Public health, Safety, MRO, COVID-19, Virus, Patient, CDC, Water, Nursing

"The latest variant, JN.1, is highly contagious and is driving transmissions, but the newest booster is helping to prevent the spread," Dr. Fletcher says.  "Yet only 20 percent of adults have received the latest vaccine.  It's important to get vaccinated -- especially high-risk patients who have underlying health conditions or are immunosuppressed."

Key Points: 
  • , public health specialist and CEO of SafeWorks Illinois , advises individuals and companies to take measures to prevent the spread of viruses and bacterial-related illnesses over the winter months.
    "
  • The latest variant, JN.1, is highly contagious and is driving transmissions, but the newest booster is helping to prevent the spread," Dr. Fletcher says.  "
  • It's important to get vaccinated -- especially high-risk patients who have underlying health conditions or are immunosuppressed."
  • SafeWorks Illinois offers worker's compensation, occupational health services and corporate programs to create safe, drug-free businesses and industries.

Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs

Retrieved on: 
Thursday, February 15, 2024
NINDS, Central nervous system, Rush University Medical Center, Giant axonal neuropathy, GM2, Rett syndrome, CNS, IP, GAN, IND, AAV, DSM-IV codes, Pharmaceutical industry

DALLAS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha” or “the Company”), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today provided an update on its deprioritized pipeline programs as part of an ongoing effort to help support their further potential development.

Key Points: 
  • DALLAS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha” or “the Company”), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today provided an update on its deprioritized pipeline programs as part of an ongoing effort to help support their further potential development.
  • Taysha has been working to find ways to advance its deprioritized programs.
  • On November 13, 2023, Taysha terminated its existing loan and security agreement and entered into a new loan and security agreement that provides consent to allow the Company to transfer intellectual property (IP) for several deprioritized programs to third parties in a more efficient manner.
  • “Today’s announcement demonstrates meaningful progress to advance important development work for several deprioritized programs.

Joshua J. Jacobs, MD, FAAOS, Receives American Academy of Orthopaedic Surgeons' Highest Leadership Honor

Retrieved on: 
Wednesday, February 14, 2024
Bangladesh Technical Education Board, SAN, Rush University Medical Center, Research, National Institutes of Health, RUSH, NIH, Rush University, Female, Orthopaedic Research Society, Orthopedic surgery, Life, Learning, Faculty, Mentorship, Rush Medical College, Patient, Health equity, Biology, AAOS, American Academy, Management

The Tipton Leadership Award recognizes AAOS members who have demonstrated outstanding leadership qualities that have benefitted the orthopaedic community, patients and/or the American public.

Key Points: 
  • The Tipton Leadership Award recognizes AAOS members who have demonstrated outstanding leadership qualities that have benefitted the orthopaedic community, patients and/or the American public.
  • "It is a distinctive honor to receive this award.
  • I had the great fortune of working with Dr. Tipton early in my career, when I was 'learning the ropes' of AAOS volunteer service," Dr. Jacobs said.
  • "He was an inspirational leader, who had the ability to evoke the best qualities in people, motivating service for a higher cause."

Molina Healthcare of Illinois Expands Provider Network to Include Rush University System for Health

Retrieved on: 
Monday, February 12, 2024
Hospitals, General Health, Health, Other Health, Hospital, Physician, Rush Copley Medical Center, Riverside Medical Center, Rush University Medical Center, Health care, Patient, Medicaid, Molina Healthcare, MMP, Marketplace, Partnership, Nursing

Molina Healthcare of Illinois (“Molina”) announced Rush University System for Health (“Rush”) is now offered as a provider for its Medicaid, Marketplace, and MMP members in the Chicagoland area.

Key Points: 
  • Molina Healthcare of Illinois (“Molina”) announced Rush University System for Health (“Rush”) is now offered as a provider for its Medicaid, Marketplace, and MMP members in the Chicagoland area.
  • “Molina is pleased to offer members greater access to top providers like Rush,” said Matt Wolf, plan president for Molina Healthcare of Illinois.
  • “Molina will be working closely with Rush as our members begin visiting its hospitals and physicians to access the latest technology, resources, and health care.”
    Molina members have access to all four Rush hospitals including Rush University Medical Center, Rush Copley Medical Center, Rush Oak Park Hospital, and Riverside Medical Center.
  • “This new partnership will create greater access to the very best health care for more patients across the Chicago area and Northwest Indiana,” said Lisa Wagamon, president of Rush Health.

Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome

Retrieved on: 
Wednesday, January 10, 2024
Ageing, Patient, CTA, MHRA, Medication, Principal, MECP2, Health care, Rush University Medical Center, AAV, Female, Rett syndrome, European Commission, Orphan drug, Risk, Mutation, Disease, Safety, Central nervous system, Caregiver, Fast Track, FDA, Index, Neurology, Adolescence, MTD, CNS, Pharmaceutical industry

DALLAS, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that the first pediatric patient has been dosed with TSHA-102 in the REVEAL Phase 1/2 pediatric trial in the United States (U.S.) evaluating the safety and preliminary efficacy of TSHA-102 in stage three female patients 5-8 years of age with Rett syndrome. The Company also announced the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the Clinical Trial Application (CTA) for TSHA-102 in pediatric patients, enabling expansion of the ongoing U.S. REVEAL pediatric trial into the U.K.

Key Points: 
  • Initiation of REVEAL pediatric trial in the U.S. broadens the clinical evaluation of TSHA-102 to female patients 5-8 years old with stage three Rett syndrome
    MHRA authorized the CTA for TSHA-102 in pediatric patients with Rett syndrome, enabling expansion of ongoing U.S.
  • “Dosing the first pediatric patient with Rett syndrome marks an important step forward in our efforts to broaden the clinical evaluation of TSHA-102 to younger patients with earlier stages of Rett syndrome.
  • “The pediatric trial will build on our ongoing REVEAL adolescent and adult trial, where early data demonstrated improvements across multiple clinical domains in adult patients with the most advanced stage of disease.
  • TSHA-102 is also being evaluated in the ongoing first-in-human REVEAL Phase 1/2 adolescent and adult trial in females aged 12 and older with Rett syndrome in Canada.

Curator Hotel & Resort Collection Expands by Adding Four Distinguished Midwest Gems to Its Growing Portfolio

Retrieved on: 
Thursday, January 11, 2024
Men, Tourist Attractions, Other Travel, Lodging, Destinations, Travel, Consumer, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Vacation, Women, REIT, Interior Design, Family, United Center, Wrigley Field, Heart, Technivorm, Collection, Sleep, Grand Hotel, Foot, Friends, Relaxation, Hip, Zoo, Hotel, Rush University Medical Center, Architectural Digest, Coffee, Common, Restaurant, UIC

“We are delighted to kick off the year by adding these four exceptional hotels in Michigan and Illinois,” said Jennifer Barnwell, President of Curator Hotel & Resort Collection.

Key Points: 
  • “We are delighted to kick off the year by adding these four exceptional hotels in Michigan and Illinois,” said Jennifer Barnwell, President of Curator Hotel & Resort Collection.
  • “Each of The Neighborhood Hotel properties combines historical elements with a hip, fresh vibe that caters to adventurers and travelers seeking respite and relaxation.
  • The Neighborhood Hotel New Buffalo (Southwest Michigan): The Neighborhood Hotel New Buffalo features nine studio suites that sleep two to four people.
  • For more information on Curator Hotel & Resort Collection, visit www.curatorhotelsandresorts.com .

North Star Vascular & Interventional Opens New Center in Minneapolis

Retrieved on: 
Wednesday, December 20, 2023
Technology, FDA, Health, Robotics, Other Health, Radiology, Surgery, Oncology, Practice Management, Medical Devices, Managed Care, General Health, Hospitals, Health Technology, Patient, Google Images, Varicocele, Artery, Pain management, Peripheral artery disease, Risk, Advocate Christ Medical Center, Knee, Physician, Uterine fibroid, Vascular disease, Intervention, Male, Infertility, Kidney disease, Chronic pain, Thyroid disease, Osteoarthritis, MBA, MD, Vein, Cancer, GE HealthCare, University, Moyamoya disease, Neoplasm, Rush University Medical Center, Fibroid, Interventional radiology, Liver cancer, Hospital-acquired infection, Pelvic congestion syndrome, Radiation, Y-90, Medical imaging

The field of vascular and interventional radiology is growing, and three area physicians have opened an outpatient center to provide viable alternatives to hospital-based surgery in Golden Valley.

Key Points: 
  • The field of vascular and interventional radiology is growing, and three area physicians have opened an outpatient center to provide viable alternatives to hospital-based surgery in Golden Valley.
  • North Star Vascular & Interventional (NSVI) offers minimally invasive procedures to treat health conditions such as peripheral artery and venous disease, cancer, enlarged prostate, uterine fibroids and more.
  • Jafar Golzarian, MD, FSIR, professor emeritus of interventional radiology at the University of Minnesota Medical School, has authored more than 400 academic articles and national and international lectures on interventional radiology.
  • Bulent Arslan, MD, FSIR is a Professor of Radiology and Chief of Interventional Radiology at the Rush University Medical Center in Chicago.

Orthofix Announces Publication in The Spine Journal of Five-Year Data for the M6-C Artificial Cervical Disc

Retrieved on: 
Wednesday, November 29, 2023
Biotechnology, Physical Therapy, Surgery, Health, FDA, Medical Devices, Clinical Trials, Other Health, Principal, Food and Drug Administration, Neck, SSI, Orthopedic surgery, Safety, Food, Radiculopathy, Spine, Clinical trial, Patient, Multimedia, ACDF, The Spine Journal, IDE, SAE, Trial of the century, Rush University Medical Center, Pain, Medical device

(NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the publication of the five-year results from the U.S. clinical study comparing the M6-C™ artificial cervical disc with anterior cervical discectomy and fusion (ACDF).

Key Points: 
  • (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the publication of the five-year results from the U.S. clinical study comparing the M6-C™ artificial cervical disc with anterior cervical discectomy and fusion (ACDF).
  • Published in The Spine Journal , patients treated with the M6-C disc demonstrated superior clinical success at 60 months compared to ACDF patients.
  • View the full release here: https://www.businesswire.com/news/home/20231129606400/en/
    The Orthofix M6-C™ artificial cervical disc is a next-generation artificial disc developed to replace an intervertebral disc damaged by cervical disc degeneration.
  • “Artificial cervical disc replacement is becoming the gold standard of care for indicated patients who may otherwise be facing cervical disc fusion.